Veeva, Boehringer Ingelheim partner to launch ‘One Medicine Platform’
Boehringer Ingelheim and Veeva Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They ...
Salipro Biotech and Boehringer Ingelheim Enter Research and License Agreement to Accelerate Multiple Boehringer Ingelheim Pipeline Programs
Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...
TMCnet7d
Boehringer Ingelheim Partners with Veeva to Launch 'One Medicine Platform'
Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases ...
Financial Post6d
Salipro Biotech and Boehringer Ingelheim Enter Research and License Agreement to Accelerate Multiple Boehringer Ingelheim Pipeline Programs
The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable ...
The Financial Express7d
Boehringer Ingelheim’s blockbuster diabetes drug goes off patent today—Will it lower treatment costs in India?
(Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin, is now off-patent in India, paving the way for domestic drugmakers to launch generic versions.
Yahoo Finance26d
Boehringer Ingelheim Pharmaceuticals, Inc. Welcomes Brian Hilberdink as President, U.S. Human Pharma
RIDGEFIELD, Conn., Feb. 20, 2025 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today the appointment of Brian Hilberdink as President, U.S ...
PharmiWeb22d
Boehringer Ingelheim launches new trivalent poultry vaccine, includes protection against H5 avian influenza
A clade is a group of viral strains that share a common ancestor. While traditional bird flu vaccines often only cover one clade at a time, Boehringer Ingelheim leveraged a technology called COBRA ...
Yahoo Finance26d
Boehringer Ingelheim Pharmaceuticals, Inc. Welcomes Brian Hilberdink as President, U.S. Human Pharma
RIDGEFIELD, Conn., Feb. 20, 2025 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today the appointment of Brian Hilberdink as President, U.S. Human Pharma. His arrival comes at a ...
The Hamilton Spectator27d
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Ingelheim, Germany, 20 February 2025 – Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial ...
The Hamilton Spectator23d
Boehringer Ingelheim launches new trivalent poultry vaccine, includes protection against H5 avian influenza
VAXXITEK® HVT+IBD+H5 is a new trivalent vaccine for poultry that offers protection against Marek’s disease, Infectious Bursal Disease and H5 avian influenza in just one shot. VAXXITEK® HVT ...
Pharm Exec23d
Boehringer Ingelheim Launches Trivalent Vaccine for H5 Avian Influenza
Launching this month, Vaxitek HVT+IBD+H5 integrates COBRA technology to address the ongoing viral evolution challenges of avian influenza, as well as for the prevention of Marek disease and infectious ...